John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test detects antihypertensive medications in urine, providing evidence of whether patients are absorbing their medications or whether a new treatment approach might be needed.

Speaker 3: (00:33)
Could you tell us a little about yourselves and your backgrounds?

Speaker 3: (01:41)
Dr. Taler, could you provide us with a brief background on resistant hypertension?

Speaker 3: (03:43)
Can you provide a little bit more background on patients who aren't taking their medications?

Speaker 3: (05:11)
How do physicians currently assess whether patients are taking their medications?

Speaker 3: (07:03)
Dr. Lieske, could you tell us how this new assay can be used to help physicians manage their patients with hypertension?

Speaker 3: (09:43)
Dr. Taler, can you tell us how doctors can use this new testing to manage their patients?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Div Dubey, M.B.B.S., a neurologist and co-director of the Clinical Neuroimmunology Laboratory at Mayo Clinic, explore the topic of peripheral neuropathy. Their discussion covers:

• The high prevalence of peripheral neuropathy and why early diagnosis is important.
• The complexities involved in diagnosing the condition.
• Symptoms that should prompt clinicians to order advanced testing early in the diagnostic process.
• How algorithms are enhancing the use of testing to complement other diagnostic tools.
• Ongoing discovery related to specific antibodies associated with neuropathies.

Learn more in our e-book, "Peripheral neuropathy: Cutting through diagnostic dissonance with an algorithmic approach."

Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay (Mayo ID: ADVQU) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in immunocompromised transplant patients, especially children.

(01:14)
Could you give us a brief overview of this assay?

(02:06)
Can you explain the differences of the qualitative and quantitative methods and why we made the change to a quantitative adenovirus method?

(04:00)
When is this test typically ordered for transplant patients? Is it used throughout their treatment?

(06:56)

Could an immunocompromised person be unknowingly infected?

(07:31)

Is our quantitative method approved for pediatric patients?

(08:00)

How are the test results used to treat patients?

(10:36)

What other infections might providers consider alongside adeovirus?